EBMT 2026 China Voice | Professor Yuqian Sun: A New Strategy for Donor Selection in Elderly Haploidentical Transplantation — Younger Donors Are Better

EBMT 2026 China Voice | Professor Yuqian Sun: A New Strategy for Donor Selection in Elderly Haploidentical Transplantation — Younger Donors Are Better

The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held from March 22 to 25, 2026, in Madrid, Spain. As one of the most influential academic events in the field, the congress brought together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy.
EBMT 2026 China Voice | Professor Xiao-Xia Hu: Refining Risk Stratification and Optimizing Decision-Making—Fusion Gene–Guided Transplant Strategies in CBF-AML 

EBMT 2026 China Voice | Professor Xiao-Xia Hu: Refining Risk Stratification and Optimizing Decision-Making—Fusion Gene–Guided Transplant Strategies in CBF-AML 

From March 22 to 25, 2026, the 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) was held in Madrid, Spain, bringing together thousands of experts worldwide to discuss the latest advances in transplantation and cellular therapy. Key topics included optimization of transplant strategies, infection control, CAR-T therapy, and graft-versus-host disease management.
ASCO GU Expert Insights | Professor Jeremy Teoh (Yuan-Jin Zhang): En Bloc Resection Redefines the Treatment Paradigm for NMIBC

ASCO GU Expert Insights | Professor Jeremy Teoh (Yuan-Jin Zhang): En Bloc Resection Redefines the Treatment Paradigm for NMIBC

At the 2026 ASCO Genitourinary Cancers Symposium (ASCO GU 2026), one of the world’s leading academic platforms in genitourinary oncology, Professor Jeremy Teoh (Yuan-Jin Zhang) and his team from The Chinese University of Hong Kong presented a series of landmark studies on en bloc resection of bladder tumor (ERBT). Backed by high-level evidence, these findings have positioned ERBT at the forefront of innovation in non–muscle-invasive bladder cancer (NMIBC), laying a solid clinical foundation for transforming treatment strategies.
EAU26 | Professor Liang-You Gu: Disitamab Vedotin Plus Immunotherapy Achieves a 1-Year DFS Rate of 97.4%, Opening New Directions for Adjuvant Treatment in High-Risk UTUC

EAU26 | Professor Liang-You Gu: Disitamab Vedotin Plus Immunotherapy Achieves a 1-Year DFS Rate of 97.4%, Opening New Directions for Adjuvant Treatment in High-Risk UTUC

With ongoing advances in research, combinations of targeted therapy and immunotherapy have become the standard first-line treatment for advanced urothelial carcinoma. However, upper tract urothelial carcinoma (UTUC) differs significantly from bladder cancer in terms of anatomical structure, pathological characteristics, prognosis, and recurrence risk. As a result, radical nephroureterectomy (RNU) remains the gold standard for non-metastatic UTUC.
ASCO GU On-site Report | Dr. Aly-Khan A. Lalani Presents CYTOSHRINK Trial Results: Early Dual Immunotherapy Combined with SBRT Shows Promise for Durable Responses in Advanced Renal Cancer

ASCO GU On-site Report | Dr. Aly-Khan A. Lalani Presents CYTOSHRINK Trial Results: Early Dual Immunotherapy Combined with SBRT Shows Promise for Durable Responses in Advanced Renal Cancer

The 2026 American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026) has successfully concluded. Numerous landmark studies in genitourinary oncology were presented, providing key evidence to inform and refine clinical practice. Among them, the phase II randomized CYTOSHRINK trial, focusing on treatment-naïve advanced renal cell carcinoma, reported its latest findings, offering important insights into the integration of immunotherapy with radiotherapy. We invited Professor Aly-Khan A. Lalani from the Juravinski Cancer Centre at McMaster University, Canada, to discuss the study design, clinical implications, and future directions in the field.
Voices from China at the EBMT Annual Meeting Prof. Jianping Zhang: High CD34⁺ Cell Dose Significantly Reduces EBV Reactivation and Improves Survival in Pediatric Aplastic Anemia Patients Undergoing UCBT

Voices from China at the EBMT Annual Meeting Prof. Jianping Zhang: High CD34⁺ Cell Dose Significantly Reduces EBV Reactivation and Improves Survival in Pediatric Aplastic Anemia Patients Undergoing UCBT

Pediatric aplastic anemia (AA) patients undergoing umbilical cord blood transplantation (UCBT) face outcomes that are closely tied to the infused cell dose. While recommended CD34⁺ cell doses have been established for hematologic malignancies, no clear standard exists for AA, leaving an important gap in clinical decision-making.
Voices from China at the EBMT Annual Meeting Prof. Peihua Lu / Prof. Yanli Zhao: Long-Term Outcomes of HSCT in Elderly Patients with Hematologic Malignancies—A Single-Center Comparison of Haploidentical, Matched Sibling, and Matched Unrelated Donors

Voices from China at the EBMT Annual Meeting Prof. Peihua Lu / Prof. Yanli Zhao: Long-Term Outcomes of HSCT in Elderly Patients with Hematologic Malignancies—A Single-Center Comparison of Haploidentical, Matched Sibling, and Matched Unrelated Donors

Allogeneic hematopoietic stem cell transplantation (HSCT) in elderly patients with hematologic malignancies remains associated with substantial treatment-related risks. Choosing among haploidentical, matched sibling, and matched unrelated donors remains challenging due to the lack of robust head-to-head comparative data.